BTAI announces results https://www.globenewswire.com/news-release/2020/07/20/2064253/0/en/BioXcel-Therapeutics-Announces-Primary-and-Secondary-Endpoints-Met-in-Two-Pivotal-Phase-3-Trials-of-BXCL501-for-the-Acute-Treatment-of-Agitation-in-Patients-with-Schizophrenia-and-.html